PMID- 32508314
OWN - NLM
STAT- Publisher
LR  - 20240227
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
DP  - 2020 Jun 1
TI  - History of the multiple endocrine neoplasia workshops and overview of MEN2019.
LID - ERC-20-0201 [pii]
LID - 10.1530/ERC-20-0201 [doi]
AB  - The multiple endocrine neoplasia (MEN) workshops had their beginnings at Queen's 
      University in Kingston, Ontario in June, 1984. This initial meeting brought 
      clinicians and scientists together to focus on mapping the gene for multiple 
      endocrine neoplasia type 2 (MEN2). These efforts culminated in the identification 
      of the RET protooncogene as the causative gene a decade later. Over the next 35 
      years there were a total of 16 international workshops focused on the several MEN 
      syndromes. Importantly, these workshops were instrumental in efforts to define 
      the molecular basis for multiple endocrine neoplasia type 1 (MEN1), MEN2, von 
      Hippel-Lindau disease (VHL), Carney Complex, hereditary pheochromocytoma and 
      hyperparathyroidism. In this same spirit some 150 scientists and clinicians met 
      at MD Anderson Cancer Center March 26-29, 2019, Houston, TX for the 16th Multiple 
      Endocrine Neoplasia (MEN) Workshop. Appropriate to its location in a cancer 
      center, the workshop focused on important issues in the causation and treatment 
      of malignant aspects of the MEN syndromes: medullary thyroid carcinoma, 
      pancreatic neuroendocrine tumors, malignant pheochromocytoma and parathyroid 
      carcinoma. Workshops at the meeting focused on a better understanding of how the 
      identified molecular defects in these genetic syndromes lead to transformation, 
      how to apply targeted kinase inhibitors and immunotherapy to treat these tumors 
      and important clinical management issues. This issue of Endocrine-Related Cancer 
      describes these discussions and recommendations.
FAU - Grubbs, Elizabeth G
AU  - Grubbs EG
AD  - E Grubbs, Departments of Surgical Oncology, University of Texas MD Anderson 
      Cancer Center, Houston, 77030-4009, United States.
FAU - Halperin, Daniel M
AU  - Halperin DM
AD  - D Halperin, Gastrointestinal Medical Oncology, University of Texas MD Anderson 
      Cancer Center, Houston, United States.
FAU - Waguespack, Steven G
AU  - Waguespack SG
AD  - S Waguespack, Endocrine Neoplasia and Hormonal Disorders, University of Texas MD 
      Anderson Cancer Center, Houston, United States.
FAU - Gagel, Robert F
AU  - Gagel RF
AD  - R Gagel, Department of Endocrine Neoplasia and Hormonal Disorders, University of 
      Texas MD Anderson Cancer Center, Houston, United States.
LA  - eng
PT  - Editorial
DEP - 20200601
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
SB  - IM
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/05/22 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
AID - ERC-20-0201 [pii]
AID - 10.1530/ERC-20-0201 [doi]
PST - aheadofprint
SO  - Endocr Relat Cancer. 2020 Jun 1:ERC-20-0201. doi: 10.1530/ERC-20-0201.